Dyax Corp. and Kadmon sign strategic licensing agreement for antibody inhibitor DX-2400
Novel MMP-14 Inhibitor to be Developed in Multi-Indication Oncology Program
24-Sep-2012 -
Dyax Corp. and Kadmon Corporation, LLC (Kadmon) announced that they have entered into a strategic licensing agreement in which Kadmon has been granted an exclusive worldwide license for the development and commercialization of the fully human monoclonal antibody DX-2400, a potent and selective ...
metalloproteinases
monoclonal antibodies
oncology